Clinical Trials Logo

Filter by:
NCT ID: NCT05895110 Completed - COVID-19 Clinical Trials

To Evaluate the Immunogenicity and Safety of Sequential Booster Immunization of Recombinant Novel Coronavirus Vaccine (CHO Cells) for SARS-CoV-2

Start date: April 29, 2022
Phase: N/A
Study type: Interventional

An open experimental design was used in this study, and 240 subjects were planned to be enrolled. To evaluate the immunogenicity and safety of recombinant Novel Coronavirus vaccine (CHO cells) after sequential intensification in populations vaccinated with two doses of marketed Novel Coronavirus inactivated vaccine.

NCT ID: NCT05894408 Completed - Clinical trials for Postoperative Nausea and Vomiting

Portal Vein Occlusion is a Valuable Predictor for Postoperative Nausea and Vomiting

Start date: June 15, 2023
Phase:
Study type: Observational

Postoperative nausea and vomiting (PONV) is one of the most common and distressing postoperative complications. PONV risk assessment is recommanded to determine the number of medications or strategies for prophylaxis. Many well-known risk factors have been determined. However, no study has explored liver surgery-specific risk factors. This study aims to identify whether there was an association between portal vein occlusion and PONV among patients after liver surgery. Patients diagnosed with liver cancer and undergoing hepatectomy will be prospectively consecutively recruited. All enrolled patients receive PONV assessments within the first 24 postoperative hours. Logistic regression models will be used to investigate the effects of portal vein occlusion and the other variables on the occurrence of PONV in both univariate and multivariate analyses

NCT ID: NCT05893615 Completed - CBT Clinical Trials

Effects of Cognitive Behavior Therapy on Quality of Life in Paroxysmal Atrial Fibrillation Patients

Start date: March 1, 2020
Phase: N/A
Study type: Interventional

Health-Related Quality of Life (HRQoL) was commonly impaired in atrial fibrillation patients. Depression, anxiety, and illness perception are psychological correlates of HRQoL. Our previous study had shown good effects of CBT on the quality of life in AF patients. This study aimed to establish the long-term efficacy of CBT on both psychological distress and HRQoL. Method: The study was a prospective, open study, pseudo-randomization with a pretest-posttest design and a 6-month follow-up. A total of 102 patients with paroxysmal AF were enrolled, and 90 patients were assigned (1:1) to 10 weeks of CBT focused on anxiety symptoms or to treat as usual in the end. Item Short Form Health Survey (SF-12), GAD-7, PHQ-9, University of Toronto Atrial Fibrillation (AFSS), and Brief Illness Perception Questionnaire (BIPQ) were measured as outcomes.

NCT ID: NCT05893576 Completed - Type 2 Diabetes Clinical Trials

A Relative Bioavailability Study of HRS9531 in Healthy Subjects

Start date: May 15, 2023
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the relative bioavailability of the new formulation of HRS9531 injection between the original formulation of HRS9531 injection.

NCT ID: NCT05890235 Completed - Chronic Prostatitis Clinical Trials

Efficacy and Safety of Ningmitai Capsule in Patients With Chronic Prostatitis/Chronic Pelvic Pain Syndrome

Start date: November 16, 2018
Phase: Phase 4
Study type: Interventional

1. Clinical trial title:Efficacy and safety of Ningmitai capsule in patients with Chronic Prostatitis/Chronic Pelvic Pain Syndrome:A prospective, randomized, positive drug-controlled, multicenter clinical study 2. Version number/date:1.0 /2018-6-24 3. Principal investigator:Zhang Xiansheng 4. Main research units:The first affiliated hospital of Anhui medical university clinical medical research ethics committee 5. Clinical trial start and end dates:2018-10-1-2022-12-31 6. Objective: To observe whether Ningmitai capsule(NMT) alone or combined with Tamsulosin for 8 weeks is more effective than Tamsulosin in improving symptoms of CP/CPPS . 7. Study type:Interventional study 8. Total sample size:300 9. Inclusion criteria: ① Age: male patients aged 18-60 years; ② Long-term and repeated pelvic discomfort or pain (NIH-CPSI pain score ≥ 4 points), lasting more than 3 months, may be accompanied by different degrees of urination symptoms and sexual dysfunction; ③ Diagnosed as type III prostatitis. Exclusion criteria: - Use any antibiotics and α1 receptor blockers in the past two weeks; ② Suffering from seminal vesiculitis, epididymitis, varicocele, tumors in prostate, bladder and urethra and other diseases affecting bladder function; - Have received transurethral resection of the prostate(TURP), transurethral incision of the prostate (TUIP), bladder neck incision, transurethral hyperthermia/radiofrequency ablation/balloon dilatation, open prostatectomy, or any other prostate surgery and treatment, such as cryotherapy; - Patients with severe cardiovascular and cerebrovascular diseases, liver, kidney and hematopoietic diseases and psychosis; ⑤ Patients who are allergic to NMT or some of its components; ⑥ Patients who are involuntarily unable to cooperate with the completion of the test. 10. Interventions: 1. NMT group Oral Ningmitai capsule, 0.38 g/capsule, tid, 4 capsules each time, after meals, for 8 weeks. Sample size:100 2. Tamsulosin group Tamsulosin Hydrochloride Sustained-release Capsules were orally administered at 0.2 mg/capsule, once daily, 1 capsule each time, for 8 weeks. Sample size:100 3.Combination group Oral Ningmitai capsule, 0.38 g/capsule, tid, 4 capsules each time, after meals, for 8 weeks.Tamsulosin Hydrochloride Sustained-release Capsules were orally administered at 0.2 mg/capsule, once daily, 1 capsule each time, for 8 weeks. Sample size:100

NCT ID: NCT05888246 Completed - Healthy People Clinical Trials

Measuring the Range of Cardiac Magnetic Parameters in Healthy Subjects by Magnetocardiogram

Start date: May 7, 2022
Phase: N/A
Study type: Interventional

A prospective and observational clinical study of measuring the range of cardiac magnetic parameters in healthy people with the magnetocardiogram manufactured by Hangzhou Nuochi Life Science Co., LTD

NCT ID: NCT05888012 Completed - Clinical trials for Chronic Pancreatitis

Balloon Catheter vs. Basket Catheter in Pancreatic Duct Stone Clearance

Start date: February 1, 2012
Phase:
Study type: Observational

The aim of the study is to compare the safety and efficacy of the basket catheter with that of the balloon catheter for endoscopic extraction of pancreatic stones.

NCT ID: NCT05887895 Completed - Diabetes Clinical Trials

To Compare the Pharmacokinetics and Pharmacodynamics of HR20014, INS068 and INS062 After Single Subcutaneous Injection in Healthy Subjects

Start date: May 23, 2023
Phase: Phase 1
Study type: Interventional

This is a single-center, randomized, open, six-sequence, three-period crossover phase I clinical trial in healthy subjects to compare the PK/PD and safety profiles of single dose of HR20014, INS068, and INS062. In this study, 12 subjects were randomly assigned to 6 administration sequences in a ratio of 1:1:1:1:1:1, and HR20014, INS068 or INS062 injection were given subcutaneously three times before and after each sequence.

NCT ID: NCT05885854 Completed - Clinical trials for Ischemic Heart Disease (IHD)

XTR003 PET Radiotracer for the Detection of Viable Myocardium

Start date: December 15, 2021
Phase: Phase 2
Study type: Interventional

The study was designed to explore the clinical feasibility of XTR003, a PET myocardial fatty-acid tracer, for the detection of viable myocardium in patients with ischemic heart disease (IHD).

NCT ID: NCT05885841 Completed - Clinical trials for Coronary Artery Disease (CAD)

Evaluation of XTR004 as a Novel 18F-labeled PET MPI Tracer in Diagnosis of Known or Suspected CAD

Start date: February 15, 2022
Phase: Phase 2
Study type: Interventional

The diagnostic efficacy and safety of the XTR004 myocardial perfusion PET imaging tracer are evaluated for known or suspected CAD with the use of invasive coronary angiography as the reference standard for the diagnosis of CAD and invasive pressure-temperature FFR/IMR as a reference for the detection of abnormal coronary function.